https://elifesciences.org/articles/09744
Biological and pharmacokinetic studies indicate that the anti-tubercular drug, delamanid, could be repurposed for the treatment of visceral leishmaniasis.
antituberculardrugdelamanidpotential
https://pubmed.ncbi.nlm.nih.gov/40613338/
The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a...
cardiac safetybedaquilinedelamanidmoxifloxacinco